Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 199 Shares

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 199 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $65.51, for a total transaction of $13,036.49. Following the completion of the sale, the insider directly owned 20,975 shares of the company’s stock, valued at approximately $1,374,072.25. The trade was a 0.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nektar Therapeutics Stock Performance

Shares of NASDAQ NKTR opened at $68.58 on Friday. Nektar Therapeutics has a one year low of $7.99 and a one year high of $109.00. The firm has a market cap of $2.32 billion, a PE ratio of -8.14 and a beta of 1.24. The firm has a fifty day moving average of $78.11 and a 200 day moving average of $61.78.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%.The business had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $10.69 million. On average, equities analysts predict that Nektar Therapeutics will post -9.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NKTR. BNP Paribas Financial Markets lifted its position in Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 210 shares during the last quarter. KBC Group NV acquired a new position in Nektar Therapeutics in the first quarter valued at about $52,000. Headlands Technologies LLC acquired a new position in Nektar Therapeutics in the second quarter valued at about $65,000. State of Wyoming acquired a new position in Nektar Therapeutics in the first quarter valued at about $67,000. Finally, Integrated Wealth Concepts LLC acquired a new position in Nektar Therapeutics in the first quarter valued at about $68,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on NKTR. Piper Sandler upped their target price on shares of Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. B. Riley Financial reaffirmed a “buy” rating and set a $150.00 target price (up from $105.00) on shares of Nektar Therapeutics in a report on Monday, February 23rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, April 22nd. HC Wainwright upped their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $140.00 target price on shares of Nektar Therapeutics in a report on Friday, March 13th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $149.63.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.